Clinical Trial Update: PSMA Therapy and Immunotherapy in Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial investigating PSMA-targeted therapy and immunotherapy for metastatic renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN